- Home
- EML vs ACHV Comparison
EML vs ACHV Comparison
Compare EML & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ACHV
- Stock Information
- Founded
- EML 1858
- ACHV N/A
- Country
- EML United States
- ACHV Canada
- Employees
- EML N/A
- ACHV N/A
- Industry
- EML Industrial Machinery/Components
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EML Consumer Discretionary
- ACHV Health Care
- Exchange
- EML Nasdaq
- ACHV Nasdaq
- Market Cap
- EML 191.3M
- ACHV 126.9M
- IPO Year
- EML N/A
- ACHV N/A
- Fundamental
- Price
- EML $26.66
- ACHV $3.15
- Analyst Decision
- EML
- ACHV Strong Buy
- Analyst Count
- EML 0
- ACHV 5
- Target Price
- EML N/A
- ACHV $14.80
- AVG Volume (30 Days)
- EML 11.4K
- ACHV 260.4K
- Earning Date
- EML 11-01-2024
- ACHV 11-07-2024
- Dividend Yield
- EML 1.66%
- ACHV N/A
- EPS Growth
- EML N/A
- ACHV N/A
- EPS
- EML N/A
- ACHV N/A
- Revenue
- EML $284,461,286.00
- ACHV N/A
- Revenue This Year
- EML N/A
- ACHV N/A
- Revenue Next Year
- EML N/A
- ACHV N/A
- P/E Ratio
- EML $13.23
- ACHV N/A
- Revenue Growth
- EML 7.70
- ACHV N/A
- 52 Week Low
- EML $22.63
- ACHV $3.12
- 52 Week High
- EML $35.78
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- EML 43.93
- ACHV 26.85
- Support Level
- EML $25.31
- ACHV $3.50
- Resistance Level
- EML $26.90
- ACHV $3.86
- Average True Range (ATR)
- EML 0.69
- ACHV 0.20
- MACD
- EML 0.00
- ACHV -0.03
- Stochastic Oscillator
- EML 54.66
- ACHV 4.05
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.